Homeworks academic writing service


Using gentamicin in the management of sepsis

J Health Popul Nutr.

Simplified Dosing of Gentamicin for Treatment of Sepsis in Bangladeshi Neonates

Monir Hossain Find articles by M. Monir Hossain Nazma A. Chowdhury Find articles by Nazma A.

  • Furthermore, the empiric treatment of patients with bloodstream infections BSI has become more complicated in an era of increasing antimicrobial resistance;
  • Pak J Med Sci;
  • Are there any other contrary reports?
  • This is a notable finding of this study.

Saha Find articles by Samir K. Correspondence and reprint requests should be addressed to: Abstract Extended-interval dosing of gentamicin has several advantages over conventional multiple-daily dosing for the treatment of sepsis.

The study was conducted to evaluate the pharmacokinetics of gentamicin for the treatment of neonatal sepsis in predetermined doses at 24- or 48-hour intervals, according to weight category, and to develop a simplified protocol for use in peripheral healthcare settings in developing countries. This prospective observational study was conducted among 59 neonates admitted to the Special Care Nursery at Dhaka Shishu Hospital, Bangladesh, with suspected sepsis and treated with antibiotics, including gentamicin.

Current Pediatric Research

Intravenous dosing of gentamicin according to weight category was: Peak and trough concentrations of gentamicin and the presence of signs of nephrotoxicity and ototoxicity were determined. No signs of nephrotoxicity or ototoxicity were detected. Favourable pharmacokinetic parameters found with the simplified dosing regimen suggest that it is safe for the treatment of neonatal sepsis.

Many neonatal deaths can be averted if the signs of infection could be recognized early by caregivers and first-line health workers and the disease is treated promptly 3 — 8. Gentamicin is a potent aminoglycoside antibiotic with bactericidal activity against Gram-negative bacteria.

Among the causative agents of neonatal sepsis, Gram-negative pathogens play a crucial role, and gentamicin is the drug of choice for first-line management. On the basis of the large volumes of distribution and slow renal clearance of aminoglycosides in neonates, larger doses based on body-weight, administered at longer intervals, are advantageous 9 — 12. To treat neonatal sepsis more effectively in low-resource settings, it is necessary to develop a strategy for extended-interval dosing of gentamicin, i.

Based on the evidence that extended-interval dosing of gentamicin has many advantages over more frequent-interval dosing regimens, we aimed at evaluating extended-interval dosing regimens for gentamcin, which were developed based on issues of pharmacokinetics, safety, frequency of dosing, body-weight of the patient, and acceptability as described previously 1314.

  1. Furthermore, we performed additional sensitivity analyses in several subgroups of patients.
  2. The study was conducted to evaluate the pharmacokinetics of gentamicin for the treatment of neonatal sepsis in predetermined doses at 24- or 48-hour intervals, according to weight category, and to develop a simplified protocol for use in peripheral healthcare settings in developing countries.
  3. Neonates up to 28 days of age, who were admitted from 15 February to 15 June 2003 for the treatment of suspected or culture-proven neonatal sepsis, were included in the study Fig.

Here, we report pharmacokinetic and safety evaluation results from the Bangladesh site of a two-site study reported elsewhere 13. Neonates up to 28 days of age, who were admitted from 15 February to 15 June 2003 for the treatment of suspected or culture-proven neonatal sepsis, were included in the study Fig. Neonates with major congenital anomalies, haemodynamic instability, or compromised renal function were excluded.

Once a potential participant was identified, a parent was counselled in the presence of a senior staff nurse, and informed written consent was obtained. All unexpected adverse events were reported to the appropriate authorities within 24 hours. The study was registered at clinicaltrials.